SCM
ATNM icon

Silverarc Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Silverarc Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-45,910
Closed -$350K – 98
2021
Q1 		$350K Sell
45,910
-44,090
-49% -$375K 0.19% 80
2020
Q4 		$702K Buy
+90,000
New +$978K 0.41% 61

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Silverarc Capital Management's ATNM Position: Q2 2021 in Review

Silverarc Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2021, closing a stake of 45,910 shares — an estimated $350K sold.

Silverarc Capital Management first reported a position in ATNM in Q4 2020 and held it in 2 quarters. The position peaked at $702K in Q4 2020. 37 funds tracked by Wall St. Rank hold ATNM as of Q2 2021.

  • Silverarc Capital Management reported no remaining Actinium Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 45,910 Actinium Pharmaceuticals shares in Q2 2021, an estimated $350K.
  • Silverarc Capital Management first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Silverarc Capital Management's Actinium Pharmaceuticals position peaked at $702K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2021.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.